周海兵 （Zhou Haibing）博士，武漢大學珞珈特聘教授、博士生導師、藥學院副院長、化學藥物研究所所長。教育部新世紀優秀人才、湖北省首屆醫學領軍人才、病毒學國家重點實驗室學術帶頭人。
從事抗腫瘤(乳腺癌) 和抗病毒藥物的設計、合成與開發，具有潛在生物活性的雜環及手性化合物的合成及方法學研究。長期從事雌激素受體（ER）的細胞特異性分子機制，和結構新穎、具有雌激素受體（ER）細胞特異信號調控功能的小分子及藥物先導結構的設計和最佳化研究。已發表SCI論文60餘篇，多篇論文發表在Nature Chemical Biology, Molecular Systems Biology, Chemistry Biology,J. Med. Chem., J. Org. Chem., Bioconjugate Chem., ChemMedChem, Adv. Synth. Catal., Bioorg. Med. Chem. Lett.等國際著名期刊上。其中以第一作者或通訊作者身份在藥物化學頂尖期刊J. Med. Chem.上發表論文8篇。主持國家自然科學基金重大研究計畫培育項目及面上項目、教育部新世紀優秀人才支持計畫項目、教育部科學技術研究重大項目、教育部博士點博導類基金等項目10餘項。
基本介紹
- 中文名：周海兵
- 外文名：Zhou Haibing
- 國籍：中國
- 職業：教授、副院長
- 畢業院校：四川大學
- 主要成就：2010年藥明康德生命化學研究獎
- 代表作品：在國外期刊上發表SCI論文近40篇
人物簡介,研究領域,研究成果,獲獎情況,
人物簡介
主要經歷:
2000年畢業於四川大學化學系有機化學專業，獲理學博士學位，導師謝如剛教授。2000年至2001年香港大學(The University of Hong Kong, with Prof. Chi-Ming Che)化學系研究助理。2001年至2003年加拿大渥太華大學（University of Ottawa, with Prof. Howard Alper)化學系博士後。2003年至2007年美國伊利諾伊大學香檳分校(University of Illinois at Urbana-Champaign, with Prof. John A. Katzenellenbogen)化學系博士後研究員。2007年至今任武漢大學藥學院教授、博士生導師。
教學課題：
主持2010年武漢大學研究生全英文課程——“高等有機化學”建設項目。
教學情況：
本科生：藥物化學
研究生：高等有機化學
博士生：藥物化學進展
社會兼職：
中國藥學會藥物化學專業委員會委員；
湖北省藥學會常務理事，藥物化學專業委員會主任委員；
“J Med Chem”、 “Tetrahedron”、“Tetrahedron Letters”、“J Heterocycle Chem”、“Curr topics in med chem”和“Bioorg. Med. Chem. Lett.” 等國際學術期刊審稿人。
研究領域
研究領域：
藥物化學、有機化學
研究興趣與方向：
1) 基於靶點（雌激素受體、HIV逆轉錄酶等）及結構生物學的新藥設計與開發。
2) 新型選擇性雌激素受體調節劑 (SERMs)、雌激素受體共激活因子結合抑制劑（CBIs）以及抗病毒藥物及前體藥物的設計、合成與開發；用於乳腺癌早期診斷(PET及納米技術等)的新型分子顯影劑的設計、合成。
3) 具有潛在生物活性的雜環化合物的新法合成及活性研究。
4) 不對稱催化及高選擇性有機合成在手性藥物及中間體合成中的套用。
承擔課題：
主持國家自然科學基金重大研究計畫培育項目及面上項目、教育部新世紀優秀人才支持計畫項目、教育部博士點博導類基金、教育部留學回國人員科研啟動基金等項目多項。
1) 主持國家自然科學基金面上項目(No. 81573279), 2016.01.01-2019.12.31。
2) 主持國家自然科學基金面上項目(No. 81373255), 2014.01-2017.12。
3) 主持湖北省醫學領軍人才培養工程項目, 2014/01--2016/12。
4) 主持武漢市創新人才開發資金資助計畫項目, 2014.01-2015.12。
5) 主持中央高校基本科研業務費專項資金拔尖創新人才資助項目(No.2042014kf0204), 2014.1 -2015.12, 已結題。
6) 主持教育部科學技術研究重大項目(No. 313040), 2013.1-2015.12。
7) 主持國家自然科學基金面上項目(No. 81172935), 2012.1-2015.12, 已結題。
8) 主持國家自然科學基金重大研究計畫培育項目(No. 91017005), 2011.1-2013.12, 已結題。
9) 主持武漢市高新技術產業科技創新團隊計畫項目(2013070204020048), 2013.1-2014.12，已結題。
10) 主持教育部新世紀優秀人才支持計畫項目(No. NCET-10-0625), 2010.1-2012.12, 已結題。
11) 主持國家自然科學基金面上項目(No. 20872116), 2009.1-2011.12, 已結題。
12) 主持高等學校博士點基金 (No. 20100141110021), 2011-2013, 已結題。
13) 國家科技部重大新藥創製專項“武漢綜合性新藥研究開發技術大平台”(No. 2009ZX09301-014-1, 參加者), 已結題。
14) 主持教育部留學回國人員科研啟動基金(No.教外司留[2009]1001), 已結題。
指導國家級大學生創新創業訓練項目：
1) 2009年度：新型選擇性雌激素受體調節劑（SERMS）的設計合成及生物活性研究（已結題並評為優秀）。
2) 2010年度：具有特殊結構的新型雌激素受體配體的設計合成及生物活性研究。
3) 2011年度：新型選擇性雌激素受體下調劑（SERDs）的設計合成及生物活性研究。
4) 2012年度：新型兼具抗乳腺癌活性和抗炎活性雌激素受體調節劑的設計、合成及其生物活性研究。
5) 2013年度：基於雙靶點的新型抗腫瘤藥物的設計、合成及生物活性研究（已結題並評為優秀）。
6) 2014年度：新型吲哚類衍生物的不對稱合成及其抗HIV生物活性研究（已結題並評為優秀）（獲第七屆全國大學生藥苑論壇優秀項目三等獎）。
7) 2016年度：新型含硒類選擇性雌激素受體調節劑（SERMs）的設計、合成及生物活性研究（梁家恩，張斌，倪智豪）。
研究成果
從事抗腫瘤、抗病毒藥物的設計、合成與開發；用於腫瘤早期診斷的新型分子顯影劑的設計、合成；具有潛在生物活性的雜環化合物的合成及方法學研究；新型手性配體及催化劑的合成及其不對稱催化反應研究等。
國際國內學術會議及報告
1) Hai-Bing Zhou, Characterization of new selective estrogen receptor downregulators (SERDs) for estrogen-sensitive and tamoxifen-resistant breast cancer. The 10th International Symposium for Chinese Medicinal Chemists (ISCMC). January 18-24, 2016, Taiwan.
2) Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong, Jian Huang, and Hai-Bing Zhou*, Novel Bioactive Conjugate Agents Targeting Both Estrogen Receptor and Histone Deacetylase for Treatment of Breast Cancer. 2015 International Chemical Congress of the Pacific Basin Societies (PacifiChem 2015). December 15-20, 2015, Ho Honolulu, Hawaii, USA.
3) Hai-Bing Zhou, Diversity-Oriented Synthesis of Novel Ligands to Improving Therapeutics that Target the Estrogen Receptor, 2015年全國藥物化學學術會議暨第五屆中英藥物化學學術會議. 2015, 8月23-26, 中國蘭州.
4) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs) of Unusual Structure and Activity: Exploring New Dimensions for Modulating Estrogen Pharmacology. Ninth International Symposium for Chinese Medicinal Chemists (ISCMC-9). August 17-20, 2014, Shenyang, China.
5) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs): Protein-Ligand Interactions and the Dual Regulation Mechanism Study. The 10th SINO-US Chemistry Professors Conference. June 15-17, 2014, Jinan, China.
6) Hai-Bing Zhou, Progress on selective estrogen receptor modulators with novel scaffolds and dual regulation activities. 第八屆全國有機化學學術會議. 2013年10月17-20, 重慶.
7) 雌激素受體的小分子雙重調控及相關藥物研究. 2013年全國藥物化學學術會議暨第四屆中英藥物化學學術會議. 2013年11月1-3, 濟南.
8) Hai-Bing Zhou, Progress in discovery of new selective estrogen receptor modulators (SERMs) based on novel structural templates. The 9th SINO-US Chemistry Professors Conference. July 12-14, 2013, Chengdu, China.
9) Hai-Bing Zhou, Novel bivalent ligands for the estrogen receptor: Design, synthesis and biological study. The 21èmes Conférences Européennes du Groupement des Pharmacochimistes de lArc Atlantique (GP2A) et 27èmes journées Franco-Belges de Pharmacochimie. June 5-7, 2013, Lille, France.
10) Hai-Bing Zhou, Study on the dual regulation of estrogen receptor with small molecules. “Ninth IUPAC International Symposium on Biomolecular Chemistry & Eighth International Symposium for Chinese Medicinal Chemists (ISCMC-8)“. August 25-29, 2012, Beijing China.
11) Hai-Bing Zhou, Novel Bifunctional Ligands for Dual Regulation of Estrogen Receptor. The 8th SINO-US Chemistry Professors Conference. July 1-4, 2012, Kunming, China.
12) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs) Based on a Diversity-Oriented Synthesis. 2011年全國藥物化學學術會議. 2011年11月17-20, 廣州.
13) Jian Min, Pengcheng Wang, Chune Dong and Hai-Bing Zhou*. Design, Synthesis and Biological Evaluation of a Novel Series of Thiophenes: Ligands Selective for Estrogen Receptor β. 第七屆全國有機化學學術會議, 2011年11月12-15, 南京.
14) Hai-Bing Zhou, Diversity-Oriented Synthesis Leads to an Effective Class of Novel Selective Estrogen Receptor Modulators (SERMs). The 7th SINO-US Chemistry Professors Conference, June 27-30, 2011, Guiyang, China
15) Hai-Bing Zhou, Yangfan Zheng, Pengcheng Wang, John A. Katzenellenbogen, Kendall W. Nettles, Modular synthesis and biological evaluation of novel estrogen receptor ligands based on a 7-thia-bicyclo[2.2.1]hept-2-ene-7-oxide or 7-oxabicyclo[2.2.1]hept-5-ene skeleton. 242nd ACS National Meeting. August 28−September 1, 2011 in Denver, Colorado.
16) Hai-Bing Zhou. Discovery and structure-based design of novel selective estrogen receptor modulators (SERMs). 中國化學會 全國第三屆有機合成化學與過程學術討論會，重慶，2010,10月18-21日.
17) Pengcheng Wang, Yangfan Zheng, Manghong Zhu, Liyan Ma, Jian Min, Chune Dong and Hai-Bing Zhou*. Synthesis and Biological Evaluation of Novel Estrogen Receptor Ligands with Bridged bicyclic Core Structures. The 7th International Symposium for Chinese Medicinal Chemists (ISCMC). February 1 to February 5, 2010, Taiwan.
論著及教材：
1) Yuzhi Lu, Ze Dong, Pengcheng Wang, and Hai-Bing Zhou*, Thiophene Oxidation and Reduction Chemistry. Topics in Heterocyclic Chemistry: Thiophenes. Chapter 6. Editors, John A. Joule, Springer International Publishing. 2015, Volume 39. Pages 227-293. DOI: 10.1007/978-3-319-07824-3.
2) 《現代製藥工藝學》（全國工程碩士專業學位教育指導委員會推薦教材）（參編）。第八章，固相化學合成製藥；第九章，化學藥物合成的新方法。趙廣榮主編，清華大學出版社出版，2015，Pages 203-303。ISBN 978-7-302-38423-6.
3) 《藥物化學》(普通高等教育“十一五”國家級規劃教材，第三版，參編)，第十六章，甾體激素藥物；第十九章，抗病毒藥。尤啟冬主編，化學工業出版社，2015，Pages 366-391；Pages 463-486。ISBN 978-7-122-24850-3.
4) 《藥物設計學》(全國普通高等醫學院校藥學類專業“十三五”規劃教材，副主編)，第三章，先導化合物發現的基本方法，2016，Pages 45-71。ISBN 978-7-5067-7885-5。
代表性論文：
已在國外期刊上發表SCI論文40多篇，多篇論文發表在Nature Chemical Biology, Chemistry Biology, J. Med. Chem., J. Org. Chem., Bioconjugate Chem., Chem. Comm., Chem.-Eur. J., Bioorg. Med. Chem. Lett.等國際著名期刊上。
1) Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain. Sathish Srinivasan, Jerome C. Nwachukwu, Nelson E. Bruno, Venkatasubramanian Dharmarajan, Devrishi Goswami, Irida Kastrati, Scott Novick, Jason Nowak, Valerie Cavett, Hai-Bing Zhou, Nittaya Boonmuen, Yuechao Zhao, Jian Min,Jonna Frasor, Be, nita S. Katzenellenbogen, Patrick R. Griffin, John A. Katzenellenbogen, Kendall W. Nettles*. Nature Chemical Biology 2016, AOP, doi:10.1038/nchembio.2236. (IF: 12.709)
2) Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Anti-Tumor Activity as an Inhibitor of Antiapoptotic Proteins. Yuzhi Lu, Shuangchan Wu, Yuan Yue, Si He, Jun Li, Jun Tang, Wei Wang,* and Hai-Bing Zhou*. ACS Med. Chem. Lett., 2016, Article ASAP. (IF: 3.355)
3) Identification and Structure–Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. Xin Han, Ningyuan Sun, Haoming Wu, Deyin Guo, Po Tien, Chune Dong, Shuwen Wu*, and Hai-Bing Zhou*. J. Med. Chem. 2016, 59 (5), 2139-2150. (IF: 5.589) (Highlighted by BioCentury Innovations (Formerly SciBX, Science-Business eXchange) on March 3, 2016)
4) Predictive Features of Ligand-Specific Signaling through the Estrogen Receptor. Jerome C. Nwachukwu, Sathish Srinivasan, Yangfan Zheng, Song Wang, Jian Min, Chune Dong, Zongquan Liao, Jason Nowak, Nicholas J. Wright, René Houtman, Kathryn E. Carlson, Jatinder S. Josan, Olivier Elemento, John A. Katzenellenbogen*, Hai-Bing Zhou*, Kendall W. Nettles*. Molecular Systems Biology 2016, 12, 864. (IF: 10.581)
5) Application of chiral squaramides:from asymmetric organocatalysis to biologically active compounds. Xin Han, Hai-Bing Zhou, Chune Dong*. Chemical Record 2016, 16 (2), 897-906. (IF: 3.459)
6) Synthesis and structure–activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy. Changhao Li, Chu Tang, Zhiye Hu, Chenxi Zhao, Chenlu Li, Silong Zhang, Chune Dong, Hai-Bing Zhou*, Jian Huang*, Bioorg. Med. Chem. 2016, 24 (13), 3062-3074. (IF: 2.923)
7) Sarah Preston, Junjie Luo, Yuezhou Zhang, Abdul Jabbar, Simon Crawford, Jonathan Baell, Andreas Hofmann, Min Hu, Hai-Bing Zhou* and Robin B. Gasser*. Selenophene and thiophene-core estrogen receptor ligands that inhibit motility and development of parasitic stages of Haemonchus contortus. Parasites & Vectors 2016,9, 346. (IF: 3.234)
8) Novel Bioactive Hybrid Compounds Dual Targeting Estrogen Receptor and Histone Deacetylase for Treatment of Breast Cancer. Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong*, Jian Huang*, and Hai-Bing Zhou*. J. Med. Chem. 2015, 58 (11), 4550-4572. (IF: 5.447)
9) Tunable Bifunctional Phosphine Squaramide Promoted Morita-Baylis-Hillman Reaction of N-alkyl Isatins with Acrylates. Ze Dong, Chao Yan, Yongzhi Gao, Chune Dong, Guofu Qiu*, Hai-Bing Zhou*. Adv. Synth. Catal. 2015, 357 (9), 2132–2142. (IF: 5.663).
10) Synthesis of N-benzyl-N-phenylthiophene-2-carboxamide Analogues as a Novel Class of Enterovirus 71 Inhibitors. Jiawei Pan, Xin Han, Ningyuan Sun, Haoming Wu, Dandan Lin, Po Tien, Hai-Bing Zhou* and Shuwen Wu*. RSC Advances 2015, 5 (31), 55100-55108. (IF: 3.840)
11) Recyclable BINOL-Quinine-Squaramide as Highly Efficient Organocatalyst for α-Amination of 1, 3-Dicarbonyl Compounds and α-Cyanoacetates. Yongzhi Gao, Bin Liu, Wei Wang, Hai-Bing Zhou and Chune Dong*. RSC Advances 2015, 5 (31), 24392-24396. (IF: 3.840)
12) Halolactones are Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. X. Han, H. Wu, C. Dong, P. Tien, W. Xie, S. W. Wu*, H.-B. Zhou*. RSC Advances 2015, 5 (13), 10005-10013. (IF: 3.840)
13) Triaryl-substituted Schiff Bases are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor. Zong-Quan Liao, Chune Dong, Kathryn E. Carlson, Sathish Srinivasan, Jerome C. Nwachukwu, Robert W. Chesnut, Abhishek Sharma, Kendall W. Nettles, John A. Katzenellenbogen,* and Hai-Bing Zhou*. J. Med. Chem. 2014, 57 (8), 3532-3545. (IF: 5.447)
14) C3-Symmetric Cinchonine-Squaramide-Catalyzed Asymmetric Chlorolactonization of Styrene-Type Carboxylic Acids with 1,3-Dichloro-5,5-dimethylhydantoin: An Efficient Method to Chiral Isochroman-1-ones. Xin Han, Chune Dong, and Hai-Bing Zhou*. Adv. Synth. Catal. 2014, 356 (6), 1275–1280. (IF: 5.663).
15) Synthesis and SARs of Indole-based α-Amino Acids as Potent HIV-1 Non-Nucleoside Reversed Transcriptase Inhibitors. Xin Han, Haoming Wu, Wei Wang, Chune Dong, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. Org. Biomol. Chem., 2014, 12 (41), 8308 - 8317. (IF: 3.562)
16) One-pot to fused pyrazoles by a double cyclization of o-alkynylaldehydes with ketones and hydrazine under metal-free condition, Jinxia Qiao, Bin Liu, Zongquan Liao, Ying Li, Lei Ma, Chune Dong, and Hai-Bing Zhou*. Tetrahedron 2014, 70 (24), 3782-3787. (IF: 2.641)
17) Thiophene-Core Estrogen Receptor Ligands Having Superagonist Activity. Jian Min, Pengcheng Wang, Sathish Srinivasan, Jerome C. Nwachukwu, Pu Guo, Minjian Huang, Kathryn E. Carlson, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. J. Med. Chem., 2013, 56 (8), 3346–3366. (IF: 5.480)
18) Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts. Xin Han, Wenjie Ouyang, Bin Liu, Wei Wang*, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. Org. Biomol. Chem., 2013, 11 (48), 8463-8475. (IF: 3.487)
19) Highly enantioselective Michael addition of 1, 3-dicarbonyl compounds to nitroalkenes catalyzed by designer chiral BINOL-Quinine-Squaramide: Efficient access to optical active nitroalkanes and their isoxazole derivatives. Bin Liu, Xin Han, Ze Dong, Hao Lv, Hai-Bing Zhou, Chune Dong*. Tetrahedron Asymmetry 2013, 24 (20), 1276-1280. (IF: 2.165)
20) Design, Synthesis and Biological Evaluation of Novel Estrogen-derived Steroidal Metal Complexes. Xinlong Zhang, Ziqing Zuo, Juan Tang, Kai Wang, Caihua Wang, Weiyan Chen, Changhao Li, Wen Xu, Xiaolin Xiong, Kangxiang Yuntai, Jian Huang, Xiaoli Lan, Hai-Bing Zhou*. Bioorg. Med. Chem. Lett. 2013, 23 (13), 3793-3797. (IF: 2.331)
21) Modification of peptides and proteins via HMDO-mediated ligation in ionic liquids. Jianli Duan, Yao Sun, Hao Chen, Guofu Qiu, Haibing Zhou, Ting Tang, Zixin Deng, Xuechuan Hong*. J. Org. Chem. 2013, 78 (14), 7013–7022. (IF: 4.638)
22) Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide. Pengcheng Wang, Jian Min, Jerome C. Nwachukwu, Valerie Cavett, Kathryn E. Carlson, Pu Guo, Manghong Zhu, Yangfan Zheng, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. J. Med. Chem. 2012, 55 (5), 2324-2341. (IF: 5.614)
23) An Expedient Approach to Highly Enantioenriched Cyclic Nitrones Mediated by Robust and Recoverable C3-Symmetric Cinchonine-Squaramide Catalysts. Xin Han, Xiangfei Wu, Chang Min, Hai-Bing Zhou, Chune Dong*. RSC Advances 2012,2 (19), 7501-7505.
24) Synthesis, biological evaluation and structure activity relationships of new estrogen receptor ligands based on a bridged oxabicyclic core embellished with arylsulfonamides. Manghong Zhu, Chen Zhang, Jerome C. Nwachukwu, Sathish Srinivasan, Valerie Cavett, Yangfan Zheng, Kathryn E. Carlson, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. Org. Biomol. Chem., 2012, 10 (43), 8692-8700. (IF: 3.568)
25) Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells. Yangfan Zheng, Caihua Wang, Changhao Li, Jinxia Qiao, Feng Zhang, Minjian Huang, Wenming Ren, Chune Dong, Jian Huang*, Hai-Bing Zhou*. Org. Biomol. Chem., 2012, 10 (48), 9689-9699. (IF: 3.568)
26) Development of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands. Yangfan Zheng, Manghong Zhu, Sathish Srinivasan, Jerome C. Nwachukwu, Valerie Cavett, Jian Min, Kathryn E. Carlson, Pengcheng Wang, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. ChemMedChem 2012, 7 (6), 1094-1100. (IF: 2.835)
27) Enhanced efficiency of recyclable C3-symmetric cinchonine-squaramides in the asymmetric Friedel–Crafts reaction of indoles with alkyl trifluoropyruvate. Xin Han, Bin Liu, Hai-Bing Zhou, Chune Dong*. Tetrahedron Asymmetry 2012, 23 (18-19), 1332-1337. (IF: 2.115)
28) Chiral Squaramide as Multiple H-Bonds Donor Organocatalyst for Asymmetric Michael addition of 1, 3-Dicarbonyl Compounds to Nitroolefins. Ze Dong, Guofu Qiu, Hai-Bing Zhou, Chune Dong*. Tetrahedron Asymmetry 2012, 23 (22-23), 1550-1556. (IF: 2.115)
29) A simple and straightforward approach toward selective C=C bond reduction by hydrazine. Hao Chen, Jianmin Wang, Xuechuan Hong, Hai-Bing Zhou, Chune Dong*. Can. J. Chem. 2012, 90 (9), 758-761. (IF: 0.964).
30) C3-Symmetric Cinchonine-Squaramide as New Highly Efficient, and Recyclable Organocatalyst for Enantioselective Michael Addition. Chang Min, Xin Han, Zongquan Liao, Xiangfei Wu, Hai-Bing Zhou, Chune Dong*. Adv. Synth. Catal. 2011, 353 (14-15), 2715–2720. (IF: 6.048).
31) Metal-free Direct Amidation of Peptidyl Thiol Esters with α-Amino Esters. Hao Chen, Maomao He, Yaya Wang, Linhui Zhai, Yongbo Cui, Yangyan Li, Yan Li, Haibing Zhou*, Xuechuan Hong* and Zixin Deng. Green. Chem. 2011, 13, 2723-2726. (IF: 6.320)
32) A Novel C3-Symmetric Prolinol-Squaramide Catalyst for the Asymmetric Reduction of Ketones by Borane. Xiang-Fei Wu, Chang Min, Hai-Bing Zhou, Chune Dong*. Tetrahedron Asymmetry 2011, 22 (16-17), 1640–1643. (IF: 2.652)
33) Highly diastereoselective synthesis of quaternary α-trifluoromethyl α-amino acids from chiral imines of trifluoropyruvate, Qiao-Qiao Min, Chun-Yang He, Haibing Zhou and Xingang Zhang, Chem. Comm. 2010, 46, 8029-8031. (IF: 5.787)
34) Imaging progesterone receptor in breast tumors: Synthesis and receptor binding affinity of fluoroalkyl-substituted analogs of Tanaproget. Hai-Bing Zhou, Jae Hak Lee, Christopher G. Mayne, Kathryn E. Carlson, John A. Katzenellenbogen*,J. Med. Chem. 2010, 53 (8), 3349–3360. (IF: 5.207)
35) Development of [F-18]Fluorine-Substituted Tanaproget as a Progesterone Receptor Imaging Agent for Positron Emission Tomography. Jae Hak Lee, Hai-Bing Zhou, Carmen S. Dence, Kathryn E. Carlson, Michael J. Welch, John A. Katzenellenbogen*, Bioconjugate Chem. 2010, 21 (6), 1096-1104. (IF: 5.002)
36) Analogs of methyl-piperidinopyrazole (MPP): Antiestrogens with estrogen receptorselective activity. Hai-Bing Zhou, Kathryn E. Carlson, Fabio Stossi, Benita S. Katzenellenbogen, John A. Katzenellenbogen*. Bioorg. Med. Chem. Lett. 2009, 19 (1), 108-110. (IF: 2.650)
37) Bromination from the Macroscopic Level to the Tracer Radiochemical Level: 76Br Radiolabeling of Aromatic Compounds via Electrophilic Substitution. Dong Zhou, Haibing Zhou, Carl C. Jenks, Jason S. Lewis, John A. Katzenellenbogen, and Michael J. Welch*. Bioconjugate Chem. 2009, 20 (4) 808-816. (IF: 4.350)
38) Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agents. Byung Chul Lee, Carmen S. Dence, Haibing Zhou, Ephraim E. Parent, Michael J. Welch, John A. Katzenellenbogen*. Nucl. Med. Biol. 2009, 36 (2) 147-153. (IF: 2.456)
39) NFkB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. K. W. Nettles*, J. B. Bruning, G. Gil, J. Nowak, S. K. Sharma, J. B. Hahm, K. Kulp, R. B. Hochberg, H. B. Zhou, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Y. Kim, A. Joachmiak, G. G. Greene, Nature Chemical Biology 2008, 4 (4), 241-247. (IF: 14.612)
40) Elemental Isomerism: A Boron-Nitrogen Surrogate for a Carbon-Carbon Double Bond Increases the Chemical Diversity of Estrogen Receptor Ligands. Hai-Bing Zhou, Kendall W. Nettles, John B. Bruning, Younchang Kim, Andrzej Joachimiak, Sanjay Sharma, Kathryn E. Carlson, Fabio Stossi, Benita S. Katzenellenbogen, Geoffrey L. Greene and John A. Katzenellenbogen*, Chemistry & Biology 2007, 14 (6), 659-669. (IF: 5.718)
41) Bicyclo[2.2.2]octanes: Close Structural Mimics of the Nuclear Receptor-binding Motif of Steroid Receptor Coactivators. Hai-Bing Zhou, Margaret L. Collins, Jillian R. Gunther, John S. Comninos and John A. Katzenellenbogen*, Bioorg. Med. Chem. Lett. 2007, 17 (15), 4118-4122. (IF: 2.604)
42) Structure-Guided Optimization of Estrogen Receptor Binding Affinity and Antagonist Potency of Pyrazolopyrimidines with Basic Side Chain. Hai-Bing Zhou, Shubin Sheng, Dennis R. Compton, Younchang Kim, Andrzej Joachimiak, Sanjay Sharma, Kathryn E. Carlson, B. S. Katzenellenbogen, Kendall W. Nettles, Geoffrey L. Greene and John A. Katzenellenbogen*, J. Med. Chem. 2007, 50 (2), 399-403. (IF: 4.895)
43) Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure. Hai-Bing Zhou, John S. Comninos, Fabio Stossi, Benita S. Katzenellenbogen, and John A. Katzenellenbogen*, J. Med. Chem. 2005, 48 (23), 7261-7274.
授權專利：
1) 周海兵，陳浩，王健民，董春娥，一種水合肼微波還原碳碳雙鍵的方法。申請日期，2010-10-25。授權日期，2013-04-03，中國專利號，ZL 201010518663.4。
2) 洪學傳，鄧子新，周海兵，陳浩等，一種醯胺類化合物的合成方法。申請日期，2011.1.13。授權日期，2013-04-24，中國專利號，ZL 201110006690.8。
3) 吳叔文，周海兵，田波，董春娥，歐陽文杰，韓欣，一種吲哚類化合物及其作為HIV-1逆轉錄酶抑制劑的套用。申請日期，2013.3.11。授權日期，2015-04-7，中國專利號，201310076738.1。
4) 董春娥，劉斌，喬金霞，周海兵，一種製備吡唑異吲哚類化合物的方法。申請日期，2013.6.9. 授權日期，2015-05-6，中國專利號，201310228096.2.
5) 周海兵，吳叔文，田波，舒紅兵，韓欣，吳浩明，一種苯並內酯類化合物及其在製備抗愛滋病藥物中的套用。申請日期，2014.5.23。申請號：201410220019.7。授權日期，2016.2.15。中國專利號：ZL201410220019.7。
6) 周海兵，吳叔文，田波，董春娥，歐陽文杰，韓欣，一種吲哚-α-胺基酸類化合物及其在製備抗愛滋病藥物中的套用。申請日期，2014.5.22。申請號：201410218599.6。授權日期，2016.1.27。中國專利號：ZL 201410218599.6。
7) 周海兵，黃健，唐初，李長浩，董春娥，張思龍，一種氧橋雙環-[2.2.1]-庚烯類化合物及其用途。申請日期，2014.9.25。申請號：201410493223.6。授權日期，2016-04-6，中國專利號，201410493223.6。
8) 王巍，吳叔文，何思，黃靖，周海兵，舒紅兵，田波，作為甲型流感病毒抑制劑的甲醯胺和異腈類化合物及其製備與套用。申請日期，2014.04.14。授權日期，2014-07-16，中國專利號，ZL201410147716.4。
9) 周海兵，吳叔文，韓欣，田波，舒紅兵，吳浩明，一種醯肼類化合物及其在製備抗手足口病藥物中的套用。申請日期，2015.4.24。申請號：201510196726.1。授權日期，2016-07-20，中國專利號，ZL201510196726.1。
獲獎情況
1) 2016年湖北省自然科學獎三等獎
2） 2013年湖北省首屆醫學領軍人才
3) 2012年武漢大學珞珈學者特聘教授
4) 2010年藥明康德生命化學研究獎
5) 2009年教育部新世紀優秀人才
